Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, cardio-metabolic and neurodegenerative diseases through its next-generation approach to selectively inhibit HDAC6. Augustine’s HDAC6 inhibitors has been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions.
Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including cardio-metabolic and neurodegenerative diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium.
Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including cardio-metabolic and neurodegenerative diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium.
Location: Belgium, East Flanders, Ghent
Employees: 1-10
Total raised: $102.34M
Founded date: 2019
Investors 4
| Date | Name | Website |
| 10.06.2025 | Jeito Capi... | jeito.life |
| - | V-Bio Vent... | v-bio.vent... |
| 09.07.2024 | Asabys Par... | asabys.com... |
| - | KU Leuven ... | lrd.kuleuv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.03.2025 | Series A | $84.2M | - |
| 26.06.2024 | Series A | $18.15M | - |
Mentions in press and media 7
| Date | Title | Description |
| 24.03.2025 | Augustine Therapeutics Raises EUR 77.7M in Series A Funding | Augustine Therapeutics, a Leuven, Belgium-based biotechnology company focused on developing new therapies through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, raised EUR 77.7M in Series A funding. The round was co-l... |
| 24.03.2025 | Augustine Therapeutics raises €78 million to develop new therapies for diseases including CMT | Leuven-based Augustine Therapeutics NV, a BioTech company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, t... |
| 26.06.2024 | Augustine Therapeutics Raises EUR 17M in Series A First Closing | Augustine Therapeutics, a Leuven, Belgium-based biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, raised EUR 17M in its first closing of Series A funding. The round was led by Asabys Partners, w... |
| 02.03.2023 | CMT Research Foundation (USA) collaborates with Augustine on new therapy against Charcot-Marie-Tooth disease | Augustine Therapeutics Logo LEUVEN, BELGIUM, March 2, 2023 /EINPresswire.com/ -- Augustine Therapeutics announces a collaboration with the Charcot-Marie-Tooth Research Foundation (CMTRF) in the USA. CMTRF is a US-based, patient-led, non-pro... |
| 10.05.2022 | Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board | Augustine Therapeutics Logo LEUVEN, BELGIUM, May 10, 2022 /EINPresswire.com/ -- Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints Gerhard Koenig as Chairman of t... |
| - | Augustine Therapeutics | “Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases” |
| - | Augustine Therapeutics | “Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.” |